Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel releasing balloon - BIOTRONIK

Next Previous
Drug Profile

Paclitaxel releasing balloon - BIOTRONIK

Alternative Names: Drug-eluting balloon - BIOTRONIK; Pantera Lux Paclitaxel Releasing Balloon; Passeo-18 Lux; Passeo-18 Lux DCB

Latest Information Update: 15 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BIOTRONIK
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • Discontinued Ischaemic heart disorders; Peripheral arterial disorders

Most Recent Events

  • 24 Sep 2021 Discontinued - Phase-II for Ischaemic heart disorders in Australia (Intracoronary)
  • 24 Sep 2021 Discontinued - Phase-II for Peripheral arterial disorders in Belgium, Germany, Austria (Intra-arterial)
  • 01 Aug 2020 Biotronik (Beijing) Medical Device completes BIOTRONIK trial for Peripheral arterial disorders in China (NCT02912715)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top